Stefanie Wolf, MD
Neurology · Athens, OHNPI 1689028656
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 249 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,258 and has fallen 52.1% since, to $602 in 2025.
Across 249 payments — averaging $15.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$661
- AbbVie$605
- SK Life Science, Inc.$501
- Lilly USA, LLC$349
- UCB, Inc.$237
- EMD Serono, Inc.$223
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,769100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 43 | $661 |
| AbbVie(2 entities) | 56 | $605 |
| SK Life Science, Inc. | 37 | $501 |
| Lilly USA, LLC | 23 | $349 |
| UCB, Inc. | 14 | $237 |
| EMD Serono, Inc. | 12 | $223 |
| Neurocrine Biosciences, Inc. | 9 | $175 |
| Bristol Myers Squibb | 8 | $133 |
| AstraZeneca | 5 | $106 |
| Eisai Inc. | 5 | $103 |
| MDD US Operations, LLC | 4 | $100 |
| Amneal Pharmaceuticals LLC | 6 | $95 |
| Jazz Pharmaceuticals Inc. | 3 | $60 |
| Impel Pharmaceuticals Inc. | 4 | $59 |
| Amgen | 3 | $51 |
| Neurelis, Inc. | 2 | $44 |
| Lundbeck LLC | 2 | $39 |
| Pfizer | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $31 |
| Livanova USA, Inc. | 1 | $25 |
| Tandem Diabetes Care, Inc. | 1 | $18 |
| Novartis | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| Banner Life Sciences, LLC | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Abbott | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
How this compares
$3,769 in reported general payments places this provider in the 65th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 18 | $190,844 |
| Nurtec OdtRimegepant Sulfate | 117 | $133,831 |
| Aimovig AutoinjectorErenumab-Aooe | 143 | $114,048 |
| UbrelvyUbrogepant | 45 | $60,112 |
| Dimethyl Fumarate | 13 | $58,909 |
| QuliptaAtogepant | 29 | $33,573 |
| Emgality PenGalcanezumab-Gnlm | 15 | $10,268 |
| RexultiBrexpiprazole | 11 | $5,460 |
| Memantine Hcl | 171 | $4,127 |
| Donepezil Hcl | 401 | $3,448 |
| Propranolol Hcl | 180 | $3,089 |
| Carbamazepine | 42 | $3,073 |
| Carbamazepine ErCarbamazepine | 16 | $2,633 |
| Gabapentin | 156 | $2,227 |
| Sumatriptan Succinate | 29 | $2,105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $34 | $133,831117 claims |
| AbbVieUbrelvy, Qulipta | $605 | $93,68674 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $16 | $5,46011 claims |
| Lilly USA, LLCOlanzapine | $349 | $2522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 702 neurology providers in Ohio.
Other neurology in Athens
- Aram ZabetiCincinnati$1.6M
- Kenneth MankowskiColumbus$1.4M
- Aaron BosterColumbus$1.2M
- Martin TaylorNew Albany$821K
- Jacqueline NicholasColumbus$743K
- Lawrence ElmerToledo$687K
- Kenneth PugarCenterville$582K
- Brendan BauerSheffield Village$548K
- Geoffrey EubankColumbus$508K
- Lawrence GoldstickDayton$479K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.